Elutia Spent a Year Selling Every Business It Owned. At $0.80, the Market Prizes the Leftover at Zero.

Elutia (Nasdaq: ELUT) presents at the H.C. Wainwright conference on September 15, a familiar box on the micro-cap calendar. This time the slot is more interesting than the typical slide deck, because it is the first major stage the company has stood on since it finished dismantling itself.

A year ago, Elutia was a working medical-device business selling antibiotic-eluting "bioenvelopes" — EluPro and CanGaroo — that wrap around cardiac implants to fight infection. In September 2025 it agreed to hand that entire line to Boston Scientific for $88 million in cash, a deal that closed October 1 and, management said, erased its debt and largely put to rest litigation tied to an earlier divestiture. Then it kept selling. In July 2026 it signed a deal to unload SimpliDerm, its dermal-matrix product, for up to $11 million, and it has floated the possibility of selling off the last small Cardiovascular piece too.

What is left is precisely one asset in development: NXT-41x, a drug-eluting biomatrix for breast reconstruction after mastectomy, plus its non-drug predecessor, NXT-41. The company sizes the U.S. market at roughly $1.5 billion and frames the hook as infection — 86% of surgeons in an independent survey said the matrices they use today raise that risk, and 96% said they'd adopt an antibiotic-eluting option.

Here is the defined sequence the conference should make or break. Elutia expects FDA clearance of the base NXT-41 matrix in the fourth quarter of 2026, clearance of the antibiotic-eluting NXT-41x in the first half of 2027, a soft launch in the second half of 2027, and a full launch the year after.

Now the part that makes the meeting worth a few minutes. The stock trades near $0.80 with a market cap of roughly $35 million. The company held $19.9 million in cash at June 30 and says it has locked in up to another $34 million from non-dilutive sources — an Avenue Capital credit facility, the $8 million escrow still owed from the Boston Scientific sale, and the SimpliDerm proceeds. Management's headline: funded through launch "without an equity offering", meaning the current share count is the floor.

That is the divergence in one line. Elutia engineered the sale of its actual revenue-generating business to pay for the product itself, at zero incremental shareholder dilution. And at a ~$35 million market cap, the equity trades close to the cash and deal proceeds the company says will carry the program — so the current price is effectively handing you the entire NXT-41x breast-reconstruction opportunity for nothing. If the FDA timeline holds and surgeons actually switch, the re-rating is structural, not a sentiment bounce.

The catch is that the case turns on exactly those two conditions, and nothing before them. The cheap price is not the thesis; the clearance is. NXT-41x is pre-revenue, the adoption survey is intent, not orders, and the standard-of-care matrices Elutia wants to displace — well-funded, heavily used — will not cede the floor because a smaller rival asked. The company also travels with scars: a history of restructuring, warrant-driven accounting swings, and litigation over products it no longer owns, which is precisely the kind of baggage the market may be pricing when it marks the equity down near cash value rather than mispricing a winner.

So on September 15, do not listen for a headline number — there is none left to report. Listen for whether management re-commits to the fourth-quarter 2026 clearance for NXT-41 and the first-half 2027 clearance for NXT-41x, and for any FDA signal that moves that cadence. That, and how much of the last Cardiovascular assets it can still squeeze out, are the only variables that change the math. Elutia has done the unglamorous work of funding its one remaining bet without dilution; what the conference has to prove is that the bet still clears on schedule, because right now the market is paying only for the cash and treating the product as a rounding error.